



**BioAlliance Pharma announces its consolidated turnover for 2009
A doubling in recurring revenues**

Paris, February 9, 2010 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced a turnover of of €7.5 million for 2009.

Loramyc[®] sales in France totaled €2.1 million - double 2008's figure and in line with the company's stated objectives. These recurring revenues confirm the success of Loramyc[®], which is increasingly being chosen by hospital-based specialists as the standard of care for oropharyngeal candidiasis. As of December 31, 2009, over 50,000 patients had received Loramyc[®].

Co-promotion of Seroplex[®] (initiated in mid-2009) generated €0.3 million in turnover. This fixed-term agreement (which expired on December 31, 2009) proved the value and the efficacy of BioAlliance Pharma's sales force. The company has just signed a new agreement with Eisai SAS France for the co-promotion of the product Aequasyl[®], indicated in the treatment of dry mouth (hyposialia). This disabling disease is very frequent in cancer patients and needs supportive care treatment.

Income from collaborations and licensing agreements totaled €5.1 million for 2009, compared with €7 million in 2008. This variation is due to the staggered payment of non-recurring revenues.

As of December 31, 2009, BioAlliance Pharma's cash reserves amounted to €14.7 million. The cash burn is in line with the company's business plan. BioAlliance Pharma expects to receive a \$20 million payment from Par Pharmaceutical/Strativa in the first half of 2010 when Loramyc[®] is granted marketing authorization in the United States. BioAlliance Pharma also expects early repayment of its 2009 research tax credit (estimated at around €2 million).

"In 2009, BioAlliance Pharma reaffirmed its positioning in supportive care with hospital-based oncologists", stated Dominique Costantini MD, BioAlliance Pharma's President and CEO. "The commercial success of Loramyc[®] in France will be very useful for our international partners - notably Par Pharmaceutical/Strativa, which is set to launch Loramyc[®] in the United States in the second half of 2010. We are confident in our ability to grow our recurring revenues in 2010 still further, with the arrival of a second product (Setofilm[®]) and the initiation of a strategic alliance within Europe".

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com